Pfizer posted second-quarter 2025 revenue of $14.65 billion, up 10 % from a year earlier and more than $1 billion above analysts’ consensus. Adjusted earnings climbed roughly 30 % to $0.78 a share, also beating projections, while reported net income reached $2.91 billion, or $0.51 a share. Performance was helped by stronger-than-expected sales of Covid-19 products Paxlovid ($427 million) and Comirnaty ($381 million) alongside continued growth from the Vyndaqel, Padcev and Eliquis franchises. On the strength of the quarter, the company lifted its full-year adjusted earnings forecast to $2.90–$3.10 a share from $2.80–$3.00, maintaining its revenue outlook of $61 billion to $64 billion. The revised guidance absorbs a one-time $0.20-per-share charge tied to a licensing deal with China’s 3SBio as well as costs from U.S. tariffs on drugs imported from China, Canada and Mexico. Management said Pfizer remains on track to deliver $7.2 billion in net cost savings by the end of 2027, with about $4.5 billion expected by 2025. The drugmaker cited operational efficiencies, a weaker dollar and disciplined spending as key drivers of margin expansion in the latest quarter.